Trophos choose Kamae Conseil to support their development

 

Trophos, a successful biotech company, has been involved in medical research on rare neurological illnesses and heart disease for the past 15 years. 2014 was a landmark year for the laboratory, as they published in March very encouraging results related to the treatment of spinal muscular atrophy (SMA), a devastating condition and a leading cause of death in babies and infants under two years old, which also causes children affected by a less severe form of SMA to suffer progressive muscle wasting and loss of mobility and motor function. To ensure that every member of staff remains as dedicated as possible to patient care, Trophos provide their managerial teams with the option to take a step back from their operational positions from time to time so they may refocus on their managerial functions. After an initial collaboration in 2011, Trophos is calling upon Kamae Conseil once again this year to run individual coaching sessions for their Managers who request them.Here, at Kamae Conseil, we feel particularly touched by such a show of confidence coming from a company built on values we feel very close to.